Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

Despite the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and, more recently, monoclonal antibodies (mAbs), in the chemotherapy regimens for newly diagnosed (NDMM) and relapsed/refractory MM (RRMM), the occurrence of drug resistance remains a challenge in MM patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Offidani, Massimo, Corvatta, Laura, Morè, Sonia, Olivieri, Attilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180291/
https://www.ncbi.nlm.nih.gov/pubmed/34103900
http://dx.doi.org/10.2147/DDDT.S267404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180291/
https://www.ncbi.nlm.nih.gov/pubmed/34103900
http://dx.doi.org/10.2147/DDDT.S267404

Ejemplares similares